Yumanity Says FDA Puts Partial Hold on YTX-7739 Studies
January 19 2022 - 8:17AM
Dow Jones News
By Colin Kellaher
Yumanity Therapeutics Inc. on Wednesday said the U.S. Food and
Drug Administration has placed a partial clinical hold on multidose
clinical trials of YTX-7739, its most advanced product candidate,
in the progressive nervous-system disorder Parkinson's disease.
The Boston clinical-stage biopharmaceutical company said the FDA
agency hasn't halted all clinical programming, and that it is
permitting a planned single-dose clinical trial to proceed.
Yumanity said it received an email notification of the partial
hold from the FDA, adding that it expects to receive more details
from the agency within 30 days.
The company said the partial hold suspends initiation of
multiple-dose clinical trials in the U.S. until it has addressed
the FDA's questions.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 19, 2022 08:02 ET (13:02 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.